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Abstract  
Purpose: E2F1 plays a critical role in cell proliferation, and its function is controlled by the 
retinoblastoma (RB) protein.  We examined the expression of E2F1 and aberration of RB 
gene and protein to elucidate what factors contribute to the overexpression of E2F1 in 
non-small cell lung carcinomas.  Methods: The expression level of E2F1 in tissues of 
non-small cell lung carcinomas was measured by means of quantitative reverse 
transcription-polymerase chain reaction and immunohistochemistry.  For RB, we examined 
loss of heterozygosity (LOH) by PCR-restriction fragment length polymorphism and variable 
number of tandem repeats, and protein expression by immunohistochemistry.  Results: 
Fifteen cases of carcinoma (46%) showed high transcription levels of E2F1 gene.  
Immunohistochemically, almost all (14 of 15) cases overexpressing E2F1 mRNA were 
positive for E2F1 protein.  LOH at the RB locus was found in 13 of 30 informative cases.  
In 13 cases with LOH, 10 showed overexpression of E2F1 mRNA and protein.  
Immunohistochemical positivity for phosphorylated RB protein was also closely correlated 
with overexpression of E2F1.  Conclusions: Our results suggest that overexpression of E2F1, 
induced both by LOH at the RB locus and anomalous phosphorylation of the RB protein, is 
involved in the development of non-small cell lung carcinoma. 
 




E2F1 protein functions as a transcription factor that enhances cell proliferation by 
binding to the promoter region of several genes that are important for cell growth control.  
Dephosphorylated RB protein binds to the transcriptionally active region of E2F1 protein, and 
inactivates E2F1.  In turn, phosphorylated RB protein releases E2F1 protein and the resultant 
free E2F1 acts as a transcription factor (Dyson 1995; Sellers et al. 1995; Weinberg 1995; Lee 
et al. 2002).  In vitro studies have revealed that overexpression of E2F1 mediates cell 
transformation (Johnson et al. 1994; Xu et al. 1995).  Gene amplification and overexpression 
of E2F1 have been reported in an erythroleukemia cell line (Saito et al. 1995).  
Overexpression of E2F1 has also been reported in tumor tissues including gastrointestinal 
carcinoma (Suzuki et al. 1999) and malignant lymphoma (Lai et al. 1998).  Thus, E2F1 is 
believed to act as an oncogene, and to play an important role in tumor progression in various 
organs.  Recently, upregulation of E2F1 has also been demonstrated in small cell lung 
carcinoma (Eymin et al. 2001) and in non-small cell lung carcinoma (Gorgoulis et al. 2002).   
The aberrant expression of E2F1 could be caused by abnormality of E2F1 itself or by 
aberrant regulation by RB protein.  The rate of gene amplification of E2F1 is low in various 
organs, including lung carcinoma (Suzuki et al. 1999, Rabbani et al. 1999, Gorgoulis et al. 
2002).  Mutation of E2F1 occurs rarely (Suzuki et al. 1999, Gorgoulis et al. 2002), whereas 
mutation of E2F4 is frequent (Ikeda et al. 1998).  These observations suggest that the main 
mechanism of E2F-1 protein overexpression is deregulation at the transcriptional level due to 
factor(s) upstream of E2F1.  The loss of function of RB protein, for example, due to a defect 
of the RB gene at 13q14, is expected to induce overexpression of E2F1.  Indeed, small cell 
lung carcinoma frequently shows allelic loss of the RB gene (Gouyer et al. 1994).  Loss of 
heterozygosity (LOH) at the RB locus has also been detected and is not a rare phenomenon 
even in non-small cell carcinoma (Xu et al. 1991; Reissmann et al. 1993; Tamura et al. 1997).  
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In addition, inactivating mutation of the other allele, leading to total loss of function of RB 
protein, is frequent in small cell lung carcinoma (Gouyer et al. 1994; Higashiyama et al. 1994).  
However, mutation is infrequent in non-small cell lung carcinoma (Sachse et al. 1994, 
Tamura et al. 1997).  Thus, the mechanism of genesis of non-small cell carcinoma could be 
different from that of small cell carcinoma.  The incidence of aberration of the RB gene and 
protein in non-small cell carcinoma is lower than that in small cell carcinoma, and it has been 
believed that loss of RB function is due to the loss of function of RB protein, which is 
regulated by phosphorylation status (Kaye 2002). Cyclin-dependent kinase and cyclin 
complex phosphorylate RB, and p16 is known to inhibit the complex.  Therefore, these 
factors are likely to affect expression of E2F1.  Inactivation of the RB pathway may occur 
through inactivation of p16 and upregulation of cyclin D1 (Brambilla 1999). 
Hyperphosphorylation of RB protein could be a marker for such aberrant control by 
cyclin-dependent kinases, cyclins and p16.  However, the phosphorylation status of RB in 
vivo in non-small cell lung carcinoma is poorly understood.  
In the present study, we examined abnormalities of E2F1 and RB in non-small cell 
lung carcinomas.  We observed overexpression of E2F1, and found a strong correlation of 
the overexpression with LOH at the RB locus and hyperphosphorylation of RB protein. 
 
Materials and methods 
Tissue samples 
Tissue samples were obtained from 33 patients with non-small cell lung carcinoma 
(17 cases of squamous cell carcinoma and 16 cases of adenocarcinoma), who were operated at 
Kanazawa University Hospital between 1996 and 1998.  Tumor tissues and non-tumor 
tissues were dissected immediately after operation.  The tissues adjacent to the area from 
which the fresh samples were dissected were fixed with 10% neutral-buffered formalin and 
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embedded in paraffin.  Informed consent was obtained from all patients enrolled in the 
study.  
Quantitative reverse transcription-polymerase chain reaction (RT-PCR)  
Total RNA was extracted from carcinoma tissue and non-tumor tissue with a total 
RNA Separator Kit (Stratagene, CA, USA), and mRNA was further purified using a poly (A) 
QuickTM mRNA purification kit (Stratagene).  The amount of mRNA of E2F1 was 
quantified by using a competitive RT-PCR method described by Riedy et al. (1995).  An 
RNA competitive reference standard (RNA-CRS) template with internal nucleotide deletions 
was created from the mRNA extracted from cultured OSC-19 cells (Kawahara et al. 1993).  
The mRNA was reverse-transcribed to cDNA with the Reverse Transcription SystemTM 
(Promega, WI, USA), and the resultant cDNA mixture was added to a standard PCR mixture.  
The primer sets were designed to amplify the E2F1 cDNA sequence (Helin et al. 1992), and 
to produce amplified cDNA which contains sequences of T7 RNA polymerase and an 80-bp 
deletion as compared with the native mRNA strand (Table I).  The sequence coding for the 
DNA binding region of the T7 RNA polymerase (underlined) was added to the upstream 
primer 
5'-AATTTAATACGACTCACTATAGGGAGAAGTCCAAGAACCACATCCAGT-3'.  The 
downstream primer 
5'-CTCAGGGCACAGGAAAACATCGATCACCATAACCATCTGCTGCTGC-3’ was 
designed to create the 80-base deletion.  The specificity of the primers was confirmed by 
sequencing the PCR product of cDNA of OSC-19 cells.  The resultant mutant cDNA was 
transcribed to RNA with a T7-MEGA ShortscriptTM kit (Ambion, Texas, USA).  Decreasing 
amounts of RNA-CRS mixed with 5 ng of sample mRNA were added to tubes along with 
upstream primer 5'-GAAGTCCAAGAACCACATCCAGT-3' for the RT followed by the 
addition of downstream primer 5'-CTCAGGGCACAGGAAAACATCG-3' for the PCR.  A 
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negative control contained all the reagents for the RT except for the RNA templates, to detect 
any contamination of RNA or DNA.  The PCR product was run in 4% agarose gel.  The gel 
was stained with ethidium bromide and visualized with an UV transilluminator.  The 
densities of the bands of RNA-CRS cDNA and the wild-type cDNA were measured using a 
densitometer.  The concentration of RNA-CRS was plotted against the ratio of the 
RNA-CRS: native RNA band densities.  Linear regression was performed and the 
equivalence point was determined.  The point where the ratio of RNA-CRS: E2F1 is equal to 
1 gives the concentration of E2F1 mRNA.  The regression plot was linear over a broad range 
and we could quantify E2F1 mRNA accurately down to the femtogram level.  To verify the 
quality and quantity of mRNA, extracts were also processed in parallel for amplification of a 
115-base pair segment of the human β2-microglobulin gene (Noonan et al. 1990). 
Restriction fragment length polymorphism (RFLP) and variable number of tandem 
repeats (VNTR) 
Genomic DNA was extracted from carcinoma tissue and non-tumor tissue with a  
DNA extraction kit (Stratagene).  Three previously published polymorphisms (introns 1, 17, 
25) in the RB gene (Bookstein et al. 1990; McGee et al. 1990; Wadayama et al. 1994) were 
analyzed by PCR-RFLP using endonucleases, BamHI, XbaI and DraI.  The PCR products 
were digested and run in an agarose gel containing ethidium bromide.  VNTR (CTTT)n in 
intron 20 was also analyzed (Wadayama et al. 1994).  The PCR product was run in 2% 
MetaphorTM agarose gel (FMC, ME, USA), and the gel was stained with ethidium bromide.  
The results of RFLP were classified into two groups: informative case when one allele was 
digested by the endonucleases and the other allele was not digested; not informative case 
when two alleles were restricted or were not restricted.  In informative cases, the cases were 
recorded as allelic loss when the tumor signal was reduced by more than 30% from the 
normal signal, in accordance with Matsumura et al. (1992), because normal cells were 
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included within the tumor.  For VNTR, the lengths of the two alleles were different in 
informative cases, but the same in non-informative cases. 
Direct Sequencing for Identification of RB Mutation 
 RB cDNA was submitted to direct sequencing of exons 12-23 using three primer sets 
(Liu et al. 1993).  The PCR products were electrophoresed in 2 % agarose gels and the 
appropriate bands were cut out.  The DNA was extracted with SUPRECTM-01 (Takara, 
Ootsu, Japan), precipitated with ethanol, and dissolved in Tris-EDTA buffer.  Direct 
sequencing was performed using a Dye Terminator Cycle Sequencing FS Ready Reaction Kit 
(Perkin Elmer, Foster City, CA, USA).  Samples were electrophoresed on an autosequencer 
(ABI PRISMTM 377 DNA Sequencer, Perkin Elmer).  
Immunohistochemistry 
E2F1, RB and phosphorylated RB proteins in formalin-fixed and paraffin-embedded 
tissue sections were detected by the streptavidin-biotin-peroxidase complex method or 
tyramide signal amplification method.  The sections were incubated with a monoclonal 
mouse antibody against E2F1 protein (clone KH95, diluted at 1 : 40, Santa Cruz 
Biotechnology, CA, USA) and RB protein (clone 3H9, diluted at 1 : 40, MBL, Nagoya, 
Japan) at 4˚C overnight and sequentially with a biotinylated anti-mouse antibody (diluted at 
1 : 200, Vector Laboratories, CA, USA) at room temperature for 30 min.  They were next 
incubated with streptavidin-biotin peroxidase complex (Jackson ImmunoResearch 
Laboratories, PA, USA).  The tyramide signal amplification method (CSAII System, 
DakoCytomation, Kyoto, Japan) using polyclonal anti-phospho-Rb (Ser807/811) antibodies 
(diluted at 1: 100, Cell Signaling Technology, Beverly, MA, USA) was applied for detection 
of phosphorylated RB protein.  Immunohistochemical nuclear stainability, regardless of 
staining intensity, was regarded as positive.  Normal mouse IgG instead of the primary 
antibody served as the negative control.  
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Statistical analysis 
Statistical analyses were made using Mann-Whitney’s U test or the χ2 test. 
 
Results 
High levels of E2F-1 mRNA in Carcinoma Tissue 
The amount of E2F1 mRNA in non-tumor tissues was always less than 2 fg/ng total 
mRNA.  Nine cases (53 %) of squamous cell carcinoma and six cases (38 %) of 
adenocarcinoma showed higher transcription levels of mRNA than the maximum level of 
non-tumor tissues, i.e., 2.0 - 41.7 fg / ng total mRNA, and this was designated as 
overexpression (Fig. 1).  The level of E2F1 mRNA in tumor tissues was significantly higher 
(p<0.005) than in non-tumor tissues, and the differences were significant in both squamous 
cell carcinoma (p<0.05) and adenocarcinoma (p<0.05).  The level tended to be higher in 
squamous cell carcinomas than in adenocarcinomas, though not significantly so.  
Correlation of E2F-1 mRNA Expression with E2F-1 Protein Expression 
The E2F1 protein was not immunohistochemically detectable in normal tissue.  We 
preliminarily examined 2 cases of small cell carcinomas, which have been reported to be 
stained positively at high frequency (Eymin et al. 2001).  Since both of them showed intense 
nuclear staining, we used the small cell carcinoma as a positive control.  In the present cases 
of non-small cell carcinoma, eight of nine squamous cell carcinomas with E2F1 mRNA 
overexpression and all six adenocarcinomas with E2F1 mRNA overexpression were positive 
with anti-E2F1 antibody (Fig. 2A, B).  The immunohistochemically positive cases and 
mRNA-overexpressing cases were thus coincident in all cases except one (Table 1).  
Correlation of E2F1 Overexpression with LOH at the RB Locus 
Four sites were examined for LOH at the RB locus, and 30 cases were 
constitutionally heterozygous in at least one of the four sites.  LOH at the RB locus was 
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found in 13 cases (42%) (Fig. 3).  Among them, seven cases (47%) of squamous cell 
carcinoma in 15 informative cases and six cases (40%) of adenocarcinoma in 15 informative 
cases showed LOH.  In 13 cases with LOH, 10 (77%) showed overexpression of E2F1 
mRNA and protein; 5 squamous cell carcinomas (70%) and 5 adenocarcinomas (83%).  
Conversely, in 14 RB-informative cases with E2F1 overexpression, 10 (71%) were 
LOH-positive, consisting of 5 squamous cell carcinomas (56%) , and 5 adenocarcinoma 
(83%), and 4 cases were negative.  In 18 cases of normal E2F1 expression, only 3 (12%) 
were LOH-positive.  There was significant difference (p<0.05) between LOH-positive cases 
and LOH-negative cases with regard to E2F1 overexpression. 
Correlation of Phosphorylated RB Protein with E2F1 Overexpression   
 RB protein and phosphorylated RB protein were also examined by an 
immunohistochemical method (Table 1).  All cases of squamous cell carcinoma and 11 cases 
of adenocarcinoma were positive.  Five cases of adenocarcinoma were judged negative, 
because RB protein-positive cells were not seen among carcinoma cells, although they were 
scattered among basal cells, endothelial cells, lymphocytes and fibroblasts.  There was no 
correlation of E2F-1 expression with immunohistochemical RB expression.   
 We used the colon tissue as a positive control for phosphorylated RB.  The crypt 
epithelia of the normal colon mucosa showed scattered immunostaining, as did germinal 
center cells in lymphoid follicles in the mucosa.  In the normal lung tissues no epithelial cell 
was immunostained, and positive germinal center cells occasionally appeared in inflamed 
lung tissue.  In carcinoma cells, phosphorylated RB protein was detected in seven cases out 
of 15 with overexpression of E2F1 (Fig. 2C, D).  Cases negative for RB protein did not show 
positive for phosphorylated RB protein.  Only 2 cases out of 18 cases without 
overexpression of E2F1 were positive.  The χ2 test showed a significant correlation between 
E2F1 overexpression and positive immunostaining for phosphorylated RB.    
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 Among 21 cases (Cases 1-7, 9, 11, 14, 17-19, 23, 24, 26, 28, 29, 31-33) for which 
RB cDNA was sequenced over exons 12-23, no mutation was found. 
 
Discussion 
 In the present quantitative study we observed at high rate of E2F1 overexpression in 
both squamous cell carcinoma and adenocarcinoma, in agreement with the findings of 
Gourgoulis et al. (2002).  E2F1 may be implicated in neoplastic transformation in a broad 
spectrum of tumors, since overexpression of E2F1 occurs in a variety of carcinomas (Eymin 
et al. 2001; Suzuki et al. 1999; Lai et al. 1998; Zhang et al. 2000).   
 LOH at the RB locus, which correlated with overexpression of E2F1, was seen in 
43% of non-small cell lung carcinoma in the present study.  Similar frequencies of LOH in 
non-small cell lung carcinoma have been reported by others: 35% (Gouyer et al. 1994), 17% 
(Xu et al. 1991), 58% (Tamura et al. 1997), and 30% (Sachse et al. 1994). LOH on 
chromosome 13q is extremely frequent in small cell carcinoma at 92% (Gouyer et al. 1994) or 
88% (Higashiyama et al. 1994).  Though the frequency of LOH was lower than in small cell 
carcinoma, it is noteworthy that 63% of squamous cell carcinomas and 83 % of 
adenocarcinomas which overexpressed E2F1 mRNA showed LOH at the RB locus.  The 
results suggest that decrease of RB protein due to LOH plays an important role in 
upregulation of E2F1, though other factors probably also contribute.   
Mutation of RB along with LOH may result in further loss of RB function in E2F-1 
regulation in small cell lung carcinoma.  We sequenced a key region called the “RB pocket” 
(exons 12 – 22), which is the binding region to E2F-1 (Nevins 1992; Xu et al. 1990), but 
found no mutation.  It is reported that mutations are infrequent in non-small cell lung 
carcinoma (Sachse et al. 1994; Tamura et al. 1997).  However, we did not examine the 
regions forward from exon 12 or back from exon 23.  Secondly, since we examined cDNA, 
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the sequence of tumor RB would not have been amplified and RB in non-tumor cells alone 
would have been amplified by RT-PCR, if the exon sequence had been altered constitutively 
due to frame shift or altered splicing, which are frequently detected in small cell carcinoma 
(Mori et al. 1990).   
Although the possibility of mutation could not be excluded, it might be unlikely in 
non-small cell lung carcinomas. However, we could detect aberrant expression of 
phosphorylated RB protein in many cases with E2F1 overexpression.  Inactivation of the RB 
pathway may result from hypermethylation of RB protein, and may occur through 
inactivation of the p16 protein and upregulation of cyclin D1.  Therefore, these factors are 
likely to affect expression of E2F1 in addition to LOH of RB presented here.  Actually, 
methylation in the promoter region of the p16 gene and allelic loss of the p16 gene leading to 
loss of p16 protein have been frequently detected in non-small cell lung carcinoma 
(Kurakawa et al. 2001; Chen et al. 2002).  In contrast, abnormal expression of cyclin D and 
p16 are infrequent in small cell lung carcinomas (Zöchbauer-Müller et al. 2002).  Since both 
overexpression of cyclin D and loss of p16 upregulate phosphorylation of RB, 
hyperphosphorylation of RB could be a characteristic abnormality of non-small cell lung 
carcinomas. 
E2F1 activity as a transcription factor is controlled by phosphorylation and 
dephosphorylation of RB protein, and free E2F1 acts as an ultimate effector of G1/S 
progression (Weinberg et al. 1995).  We did not examine the level of free E2F1, but rather 
the overall expression level of E2F1.  However, E2F1 overexpression has been thought to be 
sufficient to override the negative control of cell growth by RB protein.  It is suggested that 
LOH at the RB locus and hyperphosphorylation of RB induced the increased E2F1 level.  
An E2F1 binding domain exists in the promoter of E2F1, providing positive feedback, which 
normally induces a rapid increase of E2F1 in the G1/S transition (Johnson et al. 1994), and 
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the increase of free E2F1 stimulates E2F synthesis, enabling the overall level of E2F to 




Bookstein R, Lai C-C, To H, Lee WH (1990) PCR-based detection of polymorphic BamHI 
site in intron 1 of the human retinoblastoma (RB) gene. Nucl Acids Res 18: 1660. 
Brambilla E, Moro D, Gazzeri S, Brambilla C (1999) Alterations of expression of Rb p16 
(INK4A) and cyclin D1 in non-small cell lung carcinoma and their clinical significance. 
J Pathol 188: 351-360. 
Chen JT, Chen YC, Wang YC, Tseng RC, Chen CY, Wang YC (2002) Alterations of the 
p16(ink4a) gene in resected nonsmall cell lung tumors and exfoliated cells within sputum. 
Int J Cancer 98:724-31.         
Dyson N (1995) The regulation of E2F by pRB-family proteins. Genes Dev 12: 2245-2262. 
Eymin B, Gazzeri S, Brambilla C, Brambilla E (2001) Distinct pattern of E2F1 expression in 
human lung tumors: E2F1 is upregulated in small lung carcinoma. Oncogene 20: 
1678-1687. 
Gorgoulis VG, Zacharatos P, Mariatos G, Kotsinas A, Bouda M, Kletsas D, Asimacopoulos 
PJ, Agnantis N, Kittas C, Papavassiliou AG (2002) Transcriptional factor E2F-1 acts as a 
growth-promoting factor and is associated with adverse prognosis in non-small cell lung 
carcinomas. J Pathol 198: 142-156. 
Gouyer V, Gazzeri S, Brambilla E, Bolon I, Moro D, Perron P, Benabid AL, Brambilla C 
(1994) Loss of heterozygosity at the RB locus correlates with loss of RB protein in 
primary malignant neuroendocrine lung carcinomas. Int J Cancer 58: 818-824. 
Helin K, Lees JA, Vidal M, Dyson N, Harlow E, Fattaey A (1992) A cDNA encoding a 
pRB-binding protein with protein with properties of the transcription factor E2F. Cell 70: 
337-350. 
Higashiyama M, Doi O, Kodama K, Yokouchi H, Tateishi R (1994) Retinoblastoma protein 
expression in lung cancer: an immunohistochemical analysis. Oncology 51: 544-551. 
 14
Ikeda M, Orimo H, Moriyama H, Nakajima E, Matsubara N, Mibu R, Tanaka N, Shimada T, 
Kimura A, Shimizu K (1998) Close correlation between mutations of E2F4 and hMSH3 
genes in colorectal cancers with microsatellite instability. Cancer Res 58: 594-598. 
Johnson DG, Ohtani K, Nevins JR (1994) Autoregulatory control of E2F1 expression in 
response to positive and negative regulators of cell cycle progression. Genes Dev 8: 
1514-1525. 
Johnson DG, Cress WD, Jakoi L, Nevins JR (1994) Oncogenic capacity of the E2F1 gene. 
Proc Natl Acad Sci USA 91: 12823-12827. 
Kawahara E, Okada Y, Nakanishi I, Iwata K, Kojima S, Kumagai S, Yamamoto E. (1993) 
The expression of invasive behavior of differentiated squamous carcinoma cell line 
evaluated by an in vitro invasion model. Jpn J Cancer Res 84: 409-418. 
Kaye FJ (2002) RB and cyclin dependent kinase pathways: defining a distinction between RB 
and p16 loss in lung cancer. Oncogene 21: 6908 – 6914. 
Kurakawa E, Shimamoto T, Utsumi K, Hirano T, Kato H, Ohyashiki K (2001) 
Hypermethylation of p16 (INK4a) and p15 (INK4b) genes in non-small cell lung cancer. 
Int J Oncol 19:277-81.  
 Lee C, Chang JH, Lee HS, Cho Y (2002) Structural basis for the recognition of the E2F 
transactivation domain by the retinoblastoma tumor suppressor. Genes Dev 16: 
3199-3212. 
Lai R, Medeiros LJ, Coupl R, McCourty A, Brynes RK (1998) Immunohistochemical 
detection of E2F1 in non-Hodgkin’s lymphomas a survey of 124 cases. Mod Pathol 11: 
457-463. 
Liu Y, Szekely L, Grandér D, Söderhäll S, Juliusson G, Gahrton G, Linder S, Einhorn S 
(1993) Chronic lymphocytic leukemia cells with allelic deletions at 13q14 commonly 
have one intact RB1 gene: Evidence for a role of an adjacent locus. Proc Natl Acad Sci 
 15
USA 90: 8697-8701. 
Matsumura K, Kallioniemi A, Kallioniemi O, Chen L, Smith HS, Pinkel D, Gray J, Waldman 
FM (1992) Deletion of chromosome 17q loci in breast cancer cells detected by 
fluorescence in situ hybridization. Cancer Res 52: 3474-3477. 
McGee TL, Cowley GS, Yandell DW, Dryja TP (1990) Detection of the XbaI RFLP within 
the retinoblastoma locus by PCR. Nucl Acids Res 18: 207. 
Mori N, Yokota J, Akiyama T, Sameshima Y, Okamoto A, Mizoguchi H, Toyoshima K, 
Sugimura T, Terada M. (1990) Variable mutations of the RB gene in small-cell lung 
carcinoma. Oncogene 5:1713 – 1717. 
Nevins JR (1990) E2F: a link between the Rb tumor suppressor protein and viral oncoprotein. 
Science 258: 424-429. 
Noonan KE, Beck C, Holzmayer TA, Chin JE, Wunder JS, Andrulis IL, Gazdar AF, Willman 
CL, Griffith B, Von Hoff DD, Roninson IB (1990) Quantitative analysis of MDR1 
(multidrug resistance) gene expression in human tumors by polymerase chain reaction. 
Proc Natl Acad Sci USA 87: 7160-7164. 
Rabbani F, Richon VM, Orlow I, Lu M-L, Drobnjak M, Dudas M, Charytonowicz E, 
Dalbagni G, Cordon-Cardo C (1999) Prognostic significance of transcription factor E2F1 
in bladder cancer genotypic and phenotypic characterization. J Natl Cancer Inst 91: 
874-881. 
Reissmann PT, Koga H, Takahashi R, Figlin RA, Holmes C, Piantadosi S, Cordon-Cardo C, 
Slamon DJ, the Lung Cancer Study Group (1993) Inactivation of the retinoblastoma 
susceptibility gene in non-small-cell lung cancer. Oncogene 8: 1913-1919. 
Riedy MC, Timm EA, Stewart CC (1995) Quantitative RT-PCR for measuring gene 
expression. BioTechniques 18: 70-76. 
Sachse R, Murakami Y, Shiraishi M, Hayashi K, Sekiya T (1994) DNA aberrations at the 
 16
retinoblastoma gene locus in human squamous cell carcinomas of the lung. Oncogene 9: 
39-47. 
Saito M, Helin K, Valentine MB, Griifffith BB, Willman CL, Harlow E, Look AT (1995) 
Amplification of the E2F1 transcription factor gene in the HEL erythroleukemia cell line. 
Genomics 25: 130-138. 
Sellers WR, Rodgers JW, Kaelin WG (1995) A potent trans-repression domain in the 
retinoblastoma protein induces cell cycle arrest when bound to E2F sites. Proc Natl Acad 
Sci USA 92: 11544-11548. 
Suzuki T, Yasui W, Yokozaki H, Naka K, Ishikawa T, Tahara E (1999) Expression of the 
E2F family in human gastrointestinal carcinomas. Int J Cancer 81: 535-538. 
Tamura K, Zhang X, Murakami Y, Hirohashi S, Xu H-J, Hu S-X, Benedict WF, Sekiya T 
(1997) Deletion of three distinct regions on chromosome 13q in human non-small-cell 
lung cancer. Int J Cancer 74: 45-49. 
Wadayama B, Toguchida J, Shimizu T, Ishizaki K, Sasaki MS, Kotoura Y, Yamamuro T 
(1994) Mutation spectrum of the retinoblastoma gene in osteosarcomas. Cancer Res  
54: 3042-3048. 
Weinberg RA (1995) The retinoblastoma protein and cell cycle control. Cell 81: 323-330. 
Xu G, Livingston DM, Krek W (1995) Multiple members of the E2F transcription factor 
family are the products of oncogenes. Proc Natl Acad Sci USA 92: 1357-1361. 
Xu H-J, Hu S-X, Cagle PT, Moore GE, Benedict WF (1991) Absence of retinoblastoma 
protein expression in primary non-small cell lung carcinoma. Cancer Res 51: 2735-2739. 
Xu Q, Dyson N, Harlow E (1990) The regions of the retinoblastoma binding to adenovirus 
E1A or SV40 large T antigen are common sites for mutations. EMBO J 9: 1147-1155. 
Zhang SY, Liu SC, Al-Saleem LF, Holloran D, Babb J, Guo X, Klein-Szanto AJ (2000) 
E2F1: a proliferative marker of breast neoplasia.  Cancer Epidemiol Biomarkers Prev 9: 
 17
395-401. 
Zöchbauer-Müller S, Gazdar AF, Minna JD (2002) Molecular pathogenesis of lung cancer. 




         E2F1                       RB 
   mRNA a) Immuno          RFLP VNTR LOH Immunostain 
Case Age Sex  -stain  Intron 1 Intron 17 Intron 25 Intron 20  RB p-RB 
Squamous cell carcinoma 
1 58 M  13.9 (+)  (+) (+) NI (+) (+) (+) (+) 
2 76 M  12 (+)  (-) (+) NI (+) (+) (+) (-) 
3 75 F  12 (+)  (+) NI NI (+) (+) (+) (+) 
4 80 M  10 (+)  (-) nd NI (-) (-) (+) (+) 
5 55 M  9.5 (+)  (-) (+) NI (-) (+) (+) (+) 
6 61 M  8.2 (+)  (-) nd NI NI (-) (+) (+) 
7 70 M  6 (+)  (+) (+) (+) (+) (+) (+) (-) 
8 50 F  4 (+)  NI nd NI NI NI (+) (-) 
9 74 M  2.2 (-)  (-) (-) NI (-) (-) (+) (-) 
10 70 F  1.4 (-)  (-) nd nd nd (-) (+) (-) 
11 61 M  1.2 (-)  (-) (+) NI (+) (+) (+) (-) 
12 75 F  1 (-)  (-) nd NI NI (-) (+) (-) 
13 58 M  1 (-)  NI NI NI (-) (-) (+) (+) 
14 76 M  0.8 (-)  (+) (+) (+) (+) (+) (+) (-) 
15 71 M  0 (-)  (-) nd nd nd (-) (+) (+) 
16 71 M  0 (-)  NI NI (-) (-) (-) (+) (-) 
17 74 M  0 (-)  NI NI NI NI NI (+) (-) 
Adenocarcinoma 
18 72 F  41.7 (+)  (+) (+) (-) (+) (+) (-) (-) 
19 37 M  5.2 (+)  (+) NI (+) (+) (+) (+) (+) 
20 63 F  5 (+)  (-) (+) NI (-) (+) (+) (+) 
21 75 F  2.6 (+)  (+) (-) NI (-) (+) (+) (-) 
22 58 M  2.2 (+)  (-) (-) (-) (-) (-) (-) (-) 
23 71 F  2 (+)  (+) NI NI NI (+) (+) (-) 
24 72 F  1.8 (-)  (-) (-) (-) (-) (-) (+) (-) 
25 80 F  1.7 (-)  NI NI NI NI NI (-) (-) 
26 74 M  1.7 (-)  (-) (+) NI NI (+) (+) (-) 
17 46 F  0.9 (-)  (-) (-) (-) NI (-) (+) (-) 
28 80 F  0.7 (-)  NI NI NI (-) (-) (-) (-) 
29 77 F  0.7 (-)  (-) nd NI (-) (-) (+) (-) 
30 40 F  0.6 (-)  (-) (-) (-) NI (-) (+) (-) 
31 83 M  0.6 (-)  (-) (-) NI (-) (-) (+) (-) 
32 57 F  0 (-)  (-) nd NI (-) (-) (+) (-) 
33 58 M  0 (-)  (-) (-) NI NI (-) (-) (-) 
 
Table 1. Summary of expression of E2F1 and LOH of RB (RFLP restriction fragment length 
polymorphism, VNTR variable number tandem repeats, LOH loss of heterozygosity, NI not 
informative, nd not done, p-RB phosphorylated RB) 








Fig. 1.  Amounts of E2F1 mRNA in tumor tissues and non-tumor tissues.  The 
concentration of E2F1 was determined by quantitative RT-PCR using 5 ng of purified total 
RNA.  Final evaluation was based on the amount of E2F1 mRNA extracted from 1 ng of 
total RNA. 
 
Fig. 2.  Immunohistochemistry for E2F1 and phosphorylated RB.  E2F1-positive squamous 
cell carcinoma (A, case 1) and adenocarcinoma (B, case 21).  Phosphorylated RB-positive 
squamous cell carcinoma (C, case 15) and adenocarcinoma (D, case 20) 
 
Fig. 3.  Loss of heterozygosity (LOH) at various loci in RB.  LOH was detected on the 
basis of restriction fragment length polymorphism (RFLP) (A B C) and variable number of 
tandem repeats (VNTR) (D).  A. BamHI polymorphism in intron 1 in case 18.  B. XbaI 
polymorphism in intron 17 in case 1.  C. DraI polymorphism in intron 25 in case 14.  D. 
VNTR in intron 20 in case 7. When the tumor signal was reduced by more than 30% from the 
normal signal, the case was recorded as allelic loss, because normal cells were contained 
within the tumor.  M indicates a size marker (M1 ØX174 DNA digested with Hae III; M2 
ØX174 DNA digested with Hinf I); N non-tumor tissue; T tumor tissue; Numbers to the left 
or right side of fragments indicate fragment size (base pairs). 
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